VTAMA is a topical cream containing the active ingredient tapinarof that was approved by the FDA in May 2022 for the treatment of plaque psoriasis in adults. Tapinarof is an aryl hydrocarbon receptor agonist that works by downregulating proinflammatory cytokines and regulating skin barrier proteins. Patients apply a thin layer of VTAMA cream once daily to affected areas. Common side effects include folliculitis, nasopharyngitis, contact dermatitis, and headache. A 60g tube costs approximately $1,405 and should be stored at room temperature out of reach of children.
Related topics: